Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+19.37%
|
$960,000
$16.23 P/Share
|
|
Oct 04
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,058
-4.81%
|
$73,392
$24.77 P/Share
|
|
Sep 14
2021
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Aug 17
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,407
-4.3%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
1,407
-3.61%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,407
-3.79%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,407
-2.87%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,836
-4.76%
|
$133,212
$17.12 P/Share
|
|
Aug 17
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,407
-2.17%
|
$23,919
$17.12 P/Share
|
|
Aug 13
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+12.09%
|
-
|
|
Aug 13
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.36%
|
-
|
|
Aug 13
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.81%
|
-
|
|
Aug 13
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+8.41%
|
-
|
|
Aug 13
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+9.6%
|
-
|
|
Aug 13
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+6.48%
|
-
|
|
Jul 28
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,250
-2.73%
|
$16,250
$13.81 P/Share
|
|
Jul 16
2021
|
Steve Aselage Director |
BUY
Bona fide gift
|
Indirect |
3,000
+9.68%
|
-
|
|
Jul 16
2021
|
Steve Aselage Director |
SELL
Bona fide gift
|
Direct |
3,000
-1.82%
|
-
|
|
Jun 02
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,780
-3.14%
|
$66,920
$14.35 P/Share
|
|
Jun 01
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,782
-3.05%
|
$66,948
$14.89 P/Share
|
|
May 14
2021
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.78%
|
-
|
|
May 14
2021
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+24.0%
|
-
|
|
May 14
2021
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.78%
|
-
|
|
May 14
2021
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+4.29%
|
-
|
|
May 14
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+1.56%
|
-
|
|
May 14
2021
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.5%
|
-
|
|
May 14
2021
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+15.0%
|
-
|
|
May 14
2021
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+26.67%
|
-
|
|
May 14
2021
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.89%
|
-
|
|
May 12
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-6.62%
|
$38,000
$19.46 P/Share
|
|
May 12
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
1,625
-4.5%
|
$30,875
$19.46 P/Share
|
|
May 12
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.82%
|
$7,125
$19.46 P/Share
|
|
May 12
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,562
-4.7%
|
$29,678
$19.46 P/Share
|
|
May 11
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
2,146
-1.14%
|
$40,774
$19.58 P/Share
|
|
May 11
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-6.21%
|
$38,000
$19.14 P/Share
|
|
May 11
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
1,625
-4.31%
|
$30,875
$19.14 P/Share
|
|
May 11
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.81%
|
$7,125
$19.14 P/Share
|
|
May 11
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,563
-4.49%
|
$29,697
$19.14 P/Share
|
|
Apr 16
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.03%
|
$260,000
$26.23 P/Share
|
|
Apr 16
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.79%
|
$160,000
$16.23 P/Share
|
|
Mar 17
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
17,727
-4.38%
|
$478,629
$27.46 P/Share
|
|
Mar 17
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.62%
|
$160,000
$16.23 P/Share
|
|
Feb 18
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,250
-3.46%
|
$35,000
$28.67 P/Share
|
|
Feb 17
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,250
-3.35%
|
$33,750
$27.35 P/Share
|
|
Feb 08
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.98%
|
$149,203
$31.58 P/Share
|
|
Feb 08
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,250
-6.53%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,250
-5.63%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,250
-5.68%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.86%
|
$34,875
$31.58 P/Share
|
|
Feb 08
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,125
-2.37%
|
$34,875
$31.58 P/Share
|